Alector, Inc. (ALEC)
NASDAQ: ALEC · Real-Time Price · USD
1.240
+0.040 (3.33%)
Nov 21, 2025, 4:00 PM EST - Market closed
Alector Employees
Alector had 238 employees as of December 31, 2024. The number of employees decreased by 6 or -2.46% compared to the previous year.
Employees
238
Change (1Y)
-6
Growth (1Y)
-2.46%
Revenue / Employee
$290,118
Profits / Employee
-$452,672
Market Cap
135.35M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 238 | -6 | -2.46% |
| Dec 31, 2023 | 244 | -29 | -10.62% |
| Dec 31, 2022 | 273 | 65 | 31.25% |
| Dec 31, 2021 | 208 | 37 | 21.64% |
| Dec 31, 2020 | 171 | 50 | 41.32% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALEC News
- 4 days ago - ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 17 days ago - Alector Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce - Benzinga
- 4 weeks ago - Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic - GlobeNewsWire
- 4 weeks ago - Alector shares plunge after dementia drug fails to slow disease progression - Reuters
- 4 weeks ago - Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update - GlobeNewsWire
- 6 weeks ago - 4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga
- 2 months ago - Alector, Inc. - Special Call - Seeking Alpha